slides · global inventory
Chart
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 78,129
Current window 22,741-22,770
Pages 2,605
Rows per page 30
Component
22,741-22,770 of 78,129
22
The slide uses a grouped bar chart for price tier performance and a separate bar chart for US Spirits Super premium+ metrics.Diageo | Results Presentation Deck | 39 slides · Diageo
Conference presentation Investor relations Beat · Action2 hits
23
The charts use a stacked bar approach to show the contribution of volume and price/mix to total growth.Diageo | Results Presentation Deck | 39 slides · Diageo
Conference presentation Investor relations Beat · Action2 hits
25
The slide uses two waterfall charts to isolate the impact of LAC on operating margin performance.Diageo | Results Presentation Deck | 39 slides · Diageo
Conference presentation Investor relations Beat · ActionLoop · Before After2 hits
05
The slide uses stacked bar charts to show revenue composition over three periods (Q3 FY22-FY24).Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · What IsLoop · Benchmark Gap2 hits
06
Includes YoY and YoY constant currency (CC) growth metrics.Electronic Arts | Results Presentation Deck | 17 slides · Electronic Arts
Conference presentation Investor relations Beat · What IsLoop · Benchmark Gap2 hits
16
The slide presents two bar charts (weight and volume) and a grid of tumor photographs as visual proof of concept.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)2 hits
17
Includes visual evidence of tumor size alongside quantitative bar charts with statistical significance markers.Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)2 hits
19
The slide presents two bar charts comparing control, tumor, tumor+mock, and tumor+TD groups under different treatment conditions (IL2 vs aCD16).Enochian Biosciences | Investor Presentation Deck | 28 slides · Renovaro Biosciences
Pitch deck Investor relations Beat · Solution (Provide relief)2 hits
15
Waterfall plots showing best percentage change from baseline for two distinct patient cohorts.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · EvidenceLoop · Quick Win Big Bet2 hits
25
Shows efficacy data for ERAS-007 in combination with Encorafenib and Cetuximab.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution2 hits
26
Includes waterfall plot and swimmer plot for clinical trial results.Erasca | Investor Presentation Deck | 41 slides · Erasca
Pitch deck Investor relations Beat · Solution2 hits
10
The slide uses bar charts to visualize financial performance trends.Essity | Results Presentation Deck | 30 slides · Essity
Conference presentation Investor relations Beat · EvidenceLoop · Cost Of Inaction2 hits
11
The slide uses two bar charts to visualize financial performance over a decade.Essity | Results Presentation Deck | 30 slides · Essity
Conference presentation Investor relations Beat · EvidenceLoop · Cost Of Inaction2 hits
39
Kaplan-Meier survival curves comparing PFS1 (prior treatment) vs PFS2 (study treatment).Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
41
The slide uses a complex visual mapping to show drug response across two different biological models (patient samples vs cell lines).Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
42
The slide uses a small multiples approach to show dose-response curves for individual patient samples, followed by a summary box plot on the right.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
51
The slide presents preclinical efficacy data for a CDK7 inhibitor ('617) in ovarian (OVCAR3) and triple-negative breast cancer (HCC70) models.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
53
The slide uses a combination of a bar chart for single-agent sensitivity and a heatmap for combination synergy results.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
69
The slide uses two distinct chart types (dot plot and line chart) to demonstrate the safety profile of a reversible inhibitor compared to an irreversible one.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
70
The slide uses box plots for aggregate data and line charts for individual patient sample responses, categorized by differentiation potential.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
71
The chart compares single-agent activity (bar chart) against combination synergy (heatmap).Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
72
The slide includes two charts: a line chart showing tumour volume over time and a dot plot showing plasma pro-GRP concentration.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
85
Data shows tumor volume over time; asterisks indicate statistical significance.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
86
The slide presents experimental data comparing efficacy in CLL cells vs T-cells.Exscientia | Investor Day Presentation Deck | 90 slides · Exscientia
Conference presentation Investor relations Beat · Action2 hits
17
The slide shows a decline in Net Interest Margin despite stable Net Interest Income, and a breakdown of Non-interest Income into Strategic Program Fees and Other.FinWise Bancorp | Investor Presentation Deck | 24 slides · FinWise Bancorp
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
18
The slide highlights that the bank's capital levels are significantly above the 9% regulatory requirement.FinWise Bancorp | Investor Presentation Deck | 24 slides · FinWise Bancorp
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
19
The slide highlights a shift in portfolio mix (SBA vs Strategic Programs) to manage credit risk and reserves.FinWise Bancorp | Investor Presentation Deck | 24 slides · FinWise Bancorp
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
20
The slide uses a primary donut chart for portfolio composition and a secondary circular inset to break down interest rate exposure for a subset of the portfolio.FinWise Bancorp | Investor Presentation Deck | 24 slides · FinWise Bancorp
Pitch deck Investor relations Beat · FinancialsLoop · Cost Of Inaction2 hits
20
Includes a stacked bar chart showing revenue mix over time and a donut chart showing the breakdown of noninterest income.First Busey | Results Presentation Deck | 45 slides · First Busey Corporation
Conference presentation Investor relations Beat · SolutionLoop · Zoom In2 hits
22
Includes footnote references for revenue definition and ODFI.First Busey | Results Presentation Deck | 45 slides · First Busey Corporation
Conference presentation Investor relations 2 hits